Home › Funds › Eversept Partners, LP › BCRX

Eversept Partners, LP position in BCRX

BIOCRYST PHARMACEUTICALS INC · Health Care

Eversept Partners, LP reported holding 1,865,653 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$18.7M, representing 0.98% of its reported portfolio and ranking #30 among its reported holdings. Eversept Partners, LP has disclosed BCRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.87M sh
Reported value held$18.66M
Portfolio Weight0.98%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Eversept Partners, LP's BCRX position evolved

Eversept Partners, LP first disclosed a stake in BCRX in Q3 2023 at 2,479,103 shares (US$17.6M). The position peaked in Q1 2026 at 3,039,820 shares, worth US$28.9M. Across 12 filings, Eversept Partners, LP increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,865,653 shares valued at US$18.7M — a reduction of -1,174,167 shares quarter over quarter.. Notable position changes include a 54% trim in Q3 2024 (shares fell 1% over the following quarter), a 270% increase in Q4 2024 (shares were roughly flat over the following quarter), a 118% increase in Q4 2025 (shares rose 22% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.48M $17.55M New
Q4 2023 1.53M $9.16M Reduce
Q1 2024 1.43M $7.28M Reduce
Q2 2024 1.15M $7.12M Reduce
Q3 2024 535.40K $4.07M Reduce
Q4 2024 1.98M $14.89M Add
Q1 2025 2.17M $16.29M Add
Q2 2025 1.21M $10.82M Reduce
Q3 2025 1.37M $10.43M Add
Q4 2025 2.99M $23.34M Add
Q1 2026 3.04M $28.94M Add
Q2 2026 1.87M $18.66M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCRX and 13F data

BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCRX

All BCRX fund holders →

FAQ

How long has Eversept Partners, LP held BCRX?

Eversept Partners, LP has disclosed BCRX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Eversept Partners, LP's current position in BCRX?

As of Q2 2026, Eversept Partners, LP holds 1.87M shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $18.66M, representing 0.98% of its reported portfolio and ranking #30.

Has Eversept Partners, LP been buying or selling BCRX?

In the latest 13F filing (Q2 2026), Eversept Partners, LP reduced its position in BCRX. The position peaked in Q1 2026 at 3.04M shares.

Which other funds hold BCRX?

Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.